Showing 3201-3210 of 3314 results for "".
- Opternative Secures $9M in Most Recent Round of Fundinghttps://modernod.com/news/opternative-secures-9m-in-most-recent-round-of-funding/2479683/Opternative announced it has secured $9 million in its latest round of funding. The round of financing was led by Trust Ventures and Pritzker Group Venture Capital, with an additional investment from existing investor Jump Capital. Opternative will use the fun
- New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopiahttps://modernod.com/news/new-data-from-johnson-johnson-vision-highlights-the-need-and-potential-standards-for-evidence-based-decision-making-in-myopia/2479698/Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Te
- OCT Screening Before Cataract Surgery Can Improve Outcomeshttps://modernod.com/news/oct-screening-before-cataract-surgery-can-improve-outcomes/2479699/The routine use of optical coherence tomography (OCT) to screen candidates for cataract surgery can improve surgery timing and planning, give patients realistic expectations, and even lead to changes in treatment plans, results from a new study show, according to a Medscape
- SemaThera Board Names Garth Cumberlidge as President & CEOhttps://modernod.com/news/semathera-board-names-garth-cumberlidge-as-president-ceo/2479705/SemaThera announced that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retin
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2018 AAOpthttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2018-aaopt/2479707/Johnson & Johnson Vision will highlight new data at the 2018 American Academy of Optometry Annual Meeting (Academy 2018), held November 7-10 in San Antonio, Texas. Two paper presentations highlighting visual performance of photochromic contact lenses were designated among the “Most Newsworthy
- Ophthalmologists Implant First Visian Toric ICLs in the UShttps://modernod.com/news/ophthalmologists-implant-first-visian-toric-icls-in-the-us/2479710/Staar Surgical announced the first patient implants of the company’s Visian Toric Implantable Collamer Lenses (TICLs) in the United States by Brinton Vision in St. Louis and Parkhurst NuVision in San Antonio. A select group of lea
- Aura Biosciences Reports Positive Phase 1b/2 Clinical Data for AU-011https://modernod.com/news/aura-biosciences-reports-positive-phase-1b-2-clinical-data-for-au-011/2479713/Aura Biosciences has reported positive clinical data from its phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, its lead product candidate for the primary treatment of choroidal melanoma. “Ocular melanoma is the most
- The Retina Group of Washington Will Merge With Maryland’s Retina Associateshttps://modernod.com/news/the-retina-group-of-washington-will-merge-with-marylands-retina-associates/2479714/The Retina Group of Washington (RGW), a leading provider of retinal and macular care in the Washington, D.C., metropolitan area, has announced plans to merge with Retina Associates (RA), a 5-office practice operating in suburban Maryland locations, according to a
- Spectralis High Magnification Module Receives FDA Clearancehttps://modernod.com/news/spectralis-high-magnification-module-receives-fda-clearance/2479726/Heidelberg Engineering announced it has received FDA clearance for its Spectralis High Magnification Module. This new module consists of a highly innovative lens and software upgrade that will be available for new and
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi